Literature DB >> 6190755

Candida albicans-induced agglutinin and immunoglobulin E responses in mice.

G E Winterrowd, J E Cutler.   

Abstract

Mice varied in their ability to make detectable antibody responses to cell surface determinants of Candida albicans depending upon the antigen preparation and the immunization schedule used. Immunoglobulin M (IgM) appeared to be the major class of antibody responsible for the C. albicans-agglutinating activity of the immune sera. Various inbred strains of mice injected with a ribosomal fraction from C. albicans produced a low titer (average, 4 to 8) of yeast cell agglutinins and a higher titer (64 to 512) of IgE antibodies detected by passive cutaneous anaphylaxis (PCA) in rats. The two kinds of antibodies appeared to be specific for different antigens because the agglutinin, but not IgE, could be removed by absorbing the serum with a polysaccharide from the cell wall of C. albicans, but the polysaccharide did not provoke the PCA reaction. C. albicans-specific IgE antibodies showed cross-reactivity (PCA) with ribosomal antigens from a strain of C. albicans and C. tropicalis, but PCA reactions could not be elicited with similar antigen preparations from other yeast species. IgE responses were also detected in over 20% of the mice infected intravenously or intraperitoneally with live C. albicans.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190755      PMCID: PMC264738          DOI: 10.1128/iai.41.1.33-38.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

Review 1.  Preparation of RNA and ribosomes from yeast.

Authors:  G M Rubin
Journal:  Methods Cell Biol       Date:  1975       Impact factor: 1.441

2.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Chronic mucocutaneous candidiasis clinically exacerbated by type I hypersensitivity.

Authors:  M R Simon; D Tubergen; J Cassidy; J Silva; D Magilavy
Journal:  Clin Immunol Immunopathol       Date:  1979-09

4.  Chronic mucocutaneous candidiasis: immunologic and antibiotic therapy.

Authors:  C H Kirkpatrick; T K Smith
Journal:  Ann Intern Med       Date:  1974-03       Impact factor: 25.391

5.  Passive immunization of mice against Candida albicans.

Authors:  S Mourad; L Friedman
Journal:  Sabouraudia       Date:  1968-02

6.  Use of potato flakes agar in clinical mycology.

Authors:  M G Rinaldi
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

7.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

8.  Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

9.  Partially purified antibodies used in a solid-phase radioimmunoassay for detecting candidal antigenemia.

Authors:  A H Poor; J E Cutler
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

10.  Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions.

Authors:  R Levy; E Segal; E Eylan
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

View more
  5 in total

1.  Immunoreactivity of neoglycolipids constructed from oligomannosidic residues of the Candida albicans cell wall.

Authors:  C Faille; J C Michalski; G Strecker; D W Mackenzie; D Camus; D Poulain
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Detection of antibodies against Candida albicans ribosomes by the enzyme linked immunosorbent assay.

Authors:  R Levy; E Segal; E Eylan
Journal:  Mycopathologia       Date:  1984-09-30       Impact factor: 2.574

3.  A monoclonal antibody to a cell wall component of Candida albicans.

Authors:  V Hopwood; D Poulain; B Fortier; G Evans; A Vernes
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

4.  Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors for Candida albicans.

Authors:  Y Miyakawa; K Kagaya; Y Fukazawa; G Soe
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

5.  Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.